.ANALYSIS EMPHASIZE.16 October 2024.
In the NIAGARA litigation, the enhancement of perioperative durvalumab to standard therapy for muscle-invasive sac cancer enhanced event-free as well as on the whole survival, noting a brand new treatment possibility for this health condition.